Can Intuitive Surgical Endure the Impact of GLP-1 on Bariatric Surgery?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Source: NASDAQ.COM
Intuitive Surgical's Bariatric Surgery Challenges: Intuitive Surgical is experiencing a decline in U.S. bariatric surgery volumes due to the rise of GLP-1 weight-loss drugs, which now account for less than 3% of its da Vinci procedures. Despite this, the company is seeing growth in other surgical areas, particularly benign general surgery.
Impact on Competitors: Other medical-device companies like Medtronic and Teleflex are also facing challenges from declining bariatric procedure volumes. They are focusing on faster-growing segments and innovations to mitigate the impact of this trend.
Market Performance and Valuation: Intuitive Surgical's shares have increased by 6.5% year-to-date, outperforming the industry average. The company has a forward price-to-earnings ratio of 58.42, which is above the industry average but lower than its five-year median.
Future Growth Prospects: Despite current challenges, Intuitive Surgical is expected to see a 17.3% rise in earnings for 2025, and it holds a Zacks Rank #1 (Strong Buy), indicating positive growth potential moving forward.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TFX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TFX
Wall Street analysts forecast TFX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TFX is 136.20 USD with a low forecast of 122.00 USD and a high forecast of 155.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
1 Buy
5 Hold
1 Sell
Hold
Current: 105.480
Low
122.00
Averages
136.20
High
155.00
Current: 105.480
Low
122.00
Averages
136.20
High
155.00
About TFX
Teleflex Incorporated is a global provider of medical technologies. The Company offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of Arrow branded intra-aortic balloon pumps and catheters, GuideLiner, Turnpike and TrapLiner catheters, Pulsar-18 T3 Self-Expanding 4F Stent and Orsiro Mission Drug Eluting Stent.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eos Management Establishes New Position in Teleflex
- New Position: Eos Management disclosed a new stake in Teleflex with 30,831 shares valued at $3.76 million as of December 31, indicating a strategic investment in the medical device sector.
- Holding Proportion: This position represents 1.48% of Eos's 13F reportable assets, reflecting confidence in Teleflex's potential despite a 42.5% decline in stock price over the past year.
- Performance Outlook Adjustment: Teleflex recently narrowed its 2025 revenue growth outlook from 9.0%-10.0% to 9.1%-9.6%, highlighting operational uncertainties that may impact investor confidence.
- Strategic Focus: Teleflex is shrinking to concentrate on high-acuity hospital markets and plans to improve long-term growth and margins through divestitures, which may present future opportunities for investors.
Continue Reading
Wall Street Analysts Adjust Ratings on Key Stocks
- Affirm Holdings Upgrade: Needham analyst Kyle Peterson upgraded Affirm Holdings Inc (NASDAQ:AFRM) from Hold to Buy with a $100 price target, which, given its closing price of $68.71 on Monday, could attract more investor interest.
- CoStar Group Upgrade: BTIG analyst Jake Fuller upgraded CoStar Group Inc (NASDAQ:CSGP) from Neutral to Buy with a price target of $80, based on its closing price of $65.81 on Monday, suggesting increased market confidence following this upgrade.
- Teleflex Upgrade: Needham analyst Mike Matson upgraded Teleflex Inc (NYSE:TFX) from Hold to Buy with a target price of $138, considering its closing price of $104.20 on Monday, indicating potential upward movement in stock price due to this upgrade.
- CoreWeave Upgrade: Deutsche Bank analyst Brad Zelnick upgraded CoreWeave Inc (NASDAQ:CRWV) from Hold to Buy and raised the price target from $100 to $140, based on its closing price of $98.31 on Monday, which may trigger positive investor reactions to this rating change.
Continue Reading